Shots:
- Biogen’s decision of acquisition of TMS-007 based on the safety, imaging, and clinical outcome data from the P-IIa study which showed positive impacts on both blood vessel reopening in the brain, as well as patient functional recovery with no incidence of sICH
- TMS to receive $18M upon acquisition of TMS-007 and is eligible to receive up to $335M as post-acquisition payment upon the achievement of certain milestones along with royalties on annual WW net sales
- Biogen will be responsible for the development, manufacturing, and commercialization of TMS-007, following the acquisition and is currently assessing the next steps for the clinical development of TMS-007
Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Biogen
The post Biogen Exercises its Option to Acquire TMS-007 for Acute Ischemic Stroke first appeared on PharmaShots.
